Main Article Content
Abstract
Peripartum cardiomyopathy is a rare type of heart failure that manifests late in pregnancy or within a few months postpartum, in the absence of other causes of heart failure. Race, ethnicity, high parity, and advanced maternal age are considered important risk factors.
The etiopathogenesis of the disease is not fully understood and is likely multifactorial. Treatment includes standard pharmacological therapies for heart failure, taking into account safety considerations during pregnancy and lactation. Failure of drug therapy may require mechanical support and transplantation in severe cases.
Peripartum cardiomyopathy has a high mortality rate (up to 10%) and a high risk of recurrence in subsequent pregnancies, but more than half of women experience normalization of left ventricular function within a year of diagnosis.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
1. Bolakale-Rufai IK, Knapp SM, Johnson AE, Brewer LP, Mohammed S, Addison D, et al. Association between Race, Cardiology Care, and the receipt of Guideline Directed Medical Therapy in Peripartum Cardiomyopathy. J Racial Ethn Heal Disparities. 2023; 11(6): 3872-3881. doi: 10.1007/s40615-023-01838-5
2. Ejim EC, Karaye KM, Antia S, Isiguzo GC, Njoku PO. Peripartum cardiomyopathy in low- and middle-income countries. Best Pract Res Clin Obstet Gynaecol. 2024; 93: 102476. doi: 10.1016/j.bpobgyn.2024.102476
3. Jackson AM, Bauersachs J, Petrie MC, van der Meer P, Laroche C, Farhan HA, et al. Outcomes at one year in women with peripartum cardiomyopathy: Findings from the ESC EORP PPCM Registry. Eur J Heart Fail. 2024; 26(1): 34-42. doi: 10.1002/ejhf.3055
4. Jackson AM, Goland S, Farhan HA, Yaseen IF, Prameswari HS, Böhm M et al. A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry. Eur Heart J. 2024; 45(16): 1430-1439. doi: 10.1093/eurheartj/ehad888
5. Radakrishnan A, Dokko J, Pastena P, Kalogeropoulos AP. Thromboembolism in peripartum cardiomyopathy: a systematic review. J Thorac Dis. 2024; 16(1): 645-660. doi: 10.21037/jtd-23-945
6. Elkayam U. Safety of subsequent pregnancy after recovery from Peripartum Cardiomyopathy. J Am Coll Cardiol. 2023; 82(1): 27-29. doi: 10.1016/j.jacc.2023.04.042
7. Basic C, Schaufelberger M. Peripartum cardiomyopathy: the challenge of predicting cardiac function recovery. Eur Heart J. 2024; 45(16): 1440-1442. doi: 10.1093/eurheartj/ehae111